Product Information
LEUPROLIDE 2WK 14 MG/2.8 ML KT is a generic product labeled by PAI Holdings LLC, priced at $197.6060 per EA under NDC 00121210602. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Oct 17, 2024. Its Orange Book therapeutic-equivalence code is AP.
Manufacturer
PAI Holdings LLCNDC
00121210602
Classification
Generic
Dosage Form
KIT
Route
SUBCUTANEOUS
Effective Date
5/20/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA217957FDA Approved
10/17/2024
TE Code
AP
On Market Since
2/1/2025
Price Statistics
The NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has been published 76 times since Apr 23, 2025, and over the history we have for it it has declined 34.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $197.6060 per EA |
|---|---|
| All-time high | $301.8717 (Sep 10, 2025) |
| All-time low | $197.6060 (May 20, 2026) |
| 52-week high | $261.3184 |
| 52-week low | $197.6060 |
| Median price | $242.5177 |
| Average price | $246.0813 |
| Largest weekly change | -20.0% (Sep 17, 2025) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
leuprolide acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEUPROLIDE 2WK 14 MG/2.8 ML KT?
The current National Average Drug Acquisition Cost (NADAC) for LEUPROLIDE 2WK 14 MG/2.8 ML KT, manufactured by PAI Holdings LLC, is $197.6060 per EA (NDC 00121210602), effective Sep 30, 2026.
How has the price of LEUPROLIDE 2WK 14 MG/2.8 ML KT changed over time?
Over the history we have for it, the NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has declined 34.5%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for LEUPROLIDE 2WK 14 MG/2.8 ML KT?
Since Apr 23, 2025, the NADAC for LEUPROLIDE 2WK 14 MG/2.8 ML KT has ranged from a low of $197.6060 (May 20, 2026) to a high of $301.8717 (Sep 10, 2025), with a median of $242.5177 per EA.
Are there cheaper alternatives to LEUPROLIDE 2WK 14 MG/2.8 ML KT?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LEUPROLIDE 2WK 14 MG/2.8 ML KT in a comparable dosage form, but none are currently priced below it.
Who manufactures LEUPROLIDE 2WK 14 MG/2.8 ML KT?
LEUPROLIDE 2WK 14 MG/2.8 ML KT (NDC 00121210602) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.